



An Introduction to Imricor

November 2021



An overview of Imricor



Large addressable market, growing to over \$6bn¹ by 2024, with favourable market drivers



The world's first & only commercially available MRI compatible catheter ablation devices



Strong IP portfolio and patent protection



Experienced medical device management team



Compelling value propositions for all stakeholders



Leveraging strategic relationships with Philips Healthcare and Siemens Healthineers





Imricor enables realtime iCMR cardiac ablations



MRI compatible devices allow doctors to perform cardiac ablations using MRI instead of x-ray imaging





The significance of realtime iCMR cardiac ablations

MRI allows doctors to see the heart and to see the result of their therapy – *not possible with x-ray imaging*





A strong and growing market in cardiac ablation

A large global addressable market with high growth potential supported by favourable growth drivers

Drivers of Global Catheter Ablation Market



- Increased incidence of cardiac disease




- Shift towards minimally invasive procedures



- Cost effectiveness of catheter ablation as treatment option

Cardiac Ablation Disposables Market: US, EU, ANZ



Sources:

Millennium Research Group *Electrophysiology Mapping and Ablation Devices Europe 2021* July 2020


Millennium Research Group *Electrophysiology Mapping and Ablation Devices US 2021* June 2020

Decision Research Group, Targeted Research



The Product Portfolio

Advantage-MR EP Recorder/Stimulator System



Advantage-MR EP Recorder/Stimulator System provides proven technology that allows the physician to utilize both the EP recording system and a cardiac stimulator while ablating within the iCMR environment.

Capital Equipment

Vision-MR Ablation Catheter




The Vision-MR Ablation Catheter is an MR-Conditional (1.5T) RF ablation catheter containing patented technology that allows it to be used while the patient is being actively scanned with MRI.

It is designed to look, feel, and function like a traditional ablation catheter.

Consumable

Vision-MR Dispersive Electrode



The Vision-MR Dispersive electrode is used with the Advantage-MR EP Recorder/Stimulator system. It acts like a standard ablation dispersive electrode, but also minimizes eddy currents induced on the device's conductive pads during MR scanning.

Consumable



Delivering on our Strategic Plan

1

More **sites**
to do procedures



Grow Installed Base

2

More **procedures**
per site



Expand geographies

3

Higher **ASP** and
margin improvement



Expand indications



New product development



Disclaimer

The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc (“Imricor”) and its activities.

The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars.

This presentation may contain statements that constitute “forward-looking statements” within the meaning of Section 21E of the US Securities Exchange Act of 1934. Forward-looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding our intent, belief or current expectations with respect to our business and operations, market conditions, results of operations and financial condition.

We use words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect our current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond our control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon us. There can be no assurance that future developments will be in accordance with our expectations or that the effect of future developments on us will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Factors that may impact on the forward-looking statements made include, but are not limited to, those described in the section titled ‘Risk factors’ in Imricor’s prospectus dated 7 August 2019. When relying on forward-looking statements to make decisions with respect to us, investors and others should carefully consider such factors and other uncertainties and events. We are under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction.